T. Rowe Price Associates’s Applied Therapeutics APLT Stock Holding History

T. Rowe Price Associates’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-34,763	Closed	-$17K	–	3065
2025 Q1	$17K	Hold	34,763	–	–	﹤0.01%	3011
2024 Q4	$30K	Sell	34,763 -986,108	-97%	-$6.18M	﹤0.01%	2977
2024 Q3	$8.68M	Buy	1,020,871 +990,196	+3,228%	+$5.84M	﹤0.01%	1163
2024 Q2	$0	Buy	+30,675	New	+$145K	﹤0.01%	2925
2021 Q2	–	Sell	-11,090	Closed	-$208K	–	2918
2021 Q1	$208K	Buy	11,090 +129	+1%	+$2.78K	﹤0.01%	2678
2020 Q4	$241K	Buy	+10,961	New	+$228K	﹤0.01%	2503
2020 Q2	–	Sell	-33,385	Closed	-$1.09M	–	2494
2020 Q1	$1.09M	Buy	+33,385	New	+$1.35M	﹤0.01%	1668

Other funds holding APLT

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Associates's APLT Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Applied Therapeutics (APLT) in Q2 2025, closing a stake of 34,763 shares — an estimated $17K sold.

T. Rowe Price Associates first reported a position in APLT in Q1 2020 and held it in 7 quarters. The position peaked at $8.68M in Q3 2024. 75 funds tracked by Wall St. Rank hold APLT as of Q2 2025.

T. Rowe Price Associates reported no remaining Applied Therapeutics position as of Q2 2025 after selling out during the quarter.
T. Rowe Price Associates sold 34,763 Applied Therapeutics shares in Q2 2025, an estimated $17K.
T. Rowe Price Associates first reported a position in Applied Therapeutics in Q1 2020 and held it in 7 quarters.
T. Rowe Price Associates's Applied Therapeutics position peaked at $8.68M in Q3 2024.
75 funds tracked by Wall St. Rank held Applied Therapeutics as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.